Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
Verschueren
P
P
Lensen
F
F
Lerut
E
E
Claes
K
K
De Vos
R
R
Van Damme
B
B
Westhovens
R
R
D000328:Adult; D000686:Amyloidosis / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D000069285:Infliximab; D008297:Male; D009404:Nephrotic Syndrome / Q000628:therapy*; D025242:Spondylarthropathies / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab